Common use of Subsequent Selections Clause in Contracts

Subsequent Selections. (a) After all of the Lead Targets have been selected from the Initial Lead Target Pool, then within [*] ([*]) days after each subsequent point in time as the JRC has identified [*] ([*]) additional Lead Targets (i.e., other than KSP and the Lead Targets previously selected in accordance with this Section 2.7), and in any event at the end of Contract Year Five, the Parties shall make further selections of Collaboration Targets and CK Targets, with GSK selecting [*] ([*]) Collaboration [*], and with the [*] designated as [*] CK [*] (subject to paragraphs (b) and (c) below). For example, if [*] ([*]) Lead Targets were in the Initial Lead Target Pool, when [*] ([*]) additional Lead Targets are identified, GSK shall first select [*] ([*]) Lead Target as a Collaboration Target, and the [*] Lead Target shall be a CK Target. (b) Notwithstanding the foregoing, until such time as a total of at least [*] ([*]) Lead Targets have been identified, then the selection of such Lead Targets shall proceed in accordance with Section 2.7.1 above as if such Lead Targets had been in the Initial Lead Target Pool (i.e., so that GSK will have the right to select the first [*] Lead Targets as Collaboration [*], and CK shall have the right to select the [*] Lead Target as [*] CK [*]). (c) If there is only one (1) unselected Lead Target at the end of Contract Year Five, then that Lead Target shall be designated as a Collaboration Target or a CK Target, depending on which Party is then due a Lead Target, based on the table above.

Subsequent Selections. (a) After all of the Lead Targets have been selected from the Initial Lead Target Pool, then within [*] ([*]) days after each subsequent point in time as the JRC has identified [*] ([*]) additional Lead Targets (i.e., other than KSP [*] and the Lead Targets previously selected in accordance with this Section 2.7), and in any event at the end of Contract Year Five, the Parties shall make further selections of Collaboration Targets and CK Targets, with GSK [*] selecting [*] ([*]) Collaboration [*], and with the [*] being designated as [*] CK [*] (subject to paragraphs (b) and (c) below). For example, if [*] ([*]) Lead Targets were in the Initial Lead Target * Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. Pool, when [*] ]([*]) additional Lead Targets are identified, GSK [*] shall first select [*] ]([*]) Lead Target as a Collaboration Target[*], and the [*] Lead Target shall be a CK Target[*]. (b) Notwithstanding the foregoing, until such time as a total of at least [*] ]([*]) Lead Targets have been identified, then the selection of such Lead Targets shall proceed in accordance with Section 2.7.1 above as if such Lead Targets had been in the Initial Lead Target Pool (i.e., so that GSK [*] will have the right to select the first [*] Lead Targets as Collaboration [*], and CK [*] shall have the right to select the [*] Lead Target as [*] CK [*]). (c) If there is only one (1) unselected Lead Target at the end of Contract Year Five, then that Lead Target shall be designated as a Collaboration Target or a CK Target[*], depending on which Party is then due a Lead Target, based on the table above.

Subsequent Selections. (a) After all of the Lead Targets have been selected from the Initial Lead Target Pool, then within [*] ([*]) days after each subsequent point in time as the JRC has identified [*] ([*]) additional Lead Targets (i.e., other than KSP [*] and the Lead Targets previously selected in accordance with this Section 2.7), and in any event at the end of Contract Year Five, the Parties shall make further selections of Collaboration Targets and CK Targets, with GSK [*] selecting [*] ([*]) Collaboration [*], and with the [*] being designated as [*] CK [*] (subject to paragraphs (b) and (c) below). For example, if [*] ([*]) Lead Targets were in the Initial Lead Target Pool, when [*] ([*]) additional Lead Targets are identified, GSK [*] shall first select [*] ([*]) Lead Target as a Collaboration Target[*], and the [*] Lead Target shall be a CK Target[*]. (b) Notwithstanding the foregoing, until such time as a total of at least [*] ([*]) Lead Targets have been identified, then the selection of such Lead Targets shall proceed in accordance with Section 2.7.1 above as if such Lead Targets had been in the Initial Lead Target Pool (i.e., so that GSK [*] will have the right to select the first [*] Lead Targets as Collaboration [*], and CK [*] shall have the right to select the [*] Lead Target as [*] CK [*]). (c) If there is only one (1) unselected Lead Target at the end of Contract Year Five, then that Lead Target shall be designated as a Collaboration Target or a CK Target[*], depending on which Party is then due a Lead Target, based on the table above.